Avigen Logo
About Avigen Research & Development Pipeline Clinical Trials Investors Contact Us
 

Key Opinion Leader Testimonials of AV411 (ibudilast)

On AV411 (ibudilast) and Neuropathic Pain

“The evidence of AV411’s preclinical efficacy as well as its ability to preserve normal sensation with minimal side effects at effective dosages makes AV411 a very good clinical candidate in neuropathic pain.” (June 2006)
        Paul Rolan M.D., FRACP, FFPM     
        Professor of Clinical Pharmacology, University of Adelaide

“There is a clear need for new approaches to the treatment of neuropathic pain.  The promise of glial attenuation and AV411 is encouraging,” “A product that addresses the long-term needs of patients with this cruel affliction would be most welcome in this underserved market.” (August 2007)
        Wendye Robbins, M.D.
        Clinical Assistant Professor
        Stanford University School of Medicine

“The potential for this drug to be developed clinically for multiple pain disorders is clear.” (February 2007)
“One of the major reasons that pain is under-medicated around the world is that doctors are scared to death of making addicts. Nurses under-dose what the doctors prescribe and patients under-dose from that. If you can take that fear away, and make the drug work better, it could get people the drugs they need and working at lower doses.” (The Journal of Life Sciences, 2007)
        Linda Watkins, Ph. D.
        Professor, Department of Psychology &
        the Center for Neuroscience
        University of Colorado at Boulder

“Ibudilast enhances morphine analgesia while decreasing morphine tolerance and morphine withdrawal symptoms, and thus may have clinical utility as an opioid adjuvant to decrease dose escalation and adverse opioid side effects.” (Current Opinion on Investigational Drugs, 9:726, 2008)
       Dr. Joyce DeLeo
       Professor of Anesthesiology and Pharmacology & Toxicology
       Dartmouth Medical School

“There is a consensus in the pain community that glial activation is one of the most, if not the most, promising targets to have emerged in the last 10 years and that the only relatively near-term promising compounds are AV411 and PPF...” (December 2008 via email)
        Robert H. Dworkin, Ph.D.
        Professor of Anesthesiology, Neurology,
        Oncology, and Psychiatry
        Director, Anesthesiology Clinical Research Center
        University of Rochester School of Medicine and Dentistry

On AV411 (ibudilast) and Opioid Addiction

“NIDA has chosen to fund this study [opiod withdrawal trial in partnership with Columbia University and New York State Psychiatriac Institute] based on its review of Avigen’s research and its interest in the role of glial-attenuation as a novel way to treat opiid withdrawal symptoms, a common result of opioid abuse that can hinder recovery. This is truly an unmet medical need in this country.  The non-medical use or abuse of prescription drugs – primarily opioids – is a serious and growing public health problem.  In fact, an estimated 33 million people have used prescription drugs for non-medical reasons in their lifetimes – approximately 20 percent of the U.S. population.” (September 2008)
        Frank J. Vocci, Ph.D.
        Director of the Division of Pharmacotherapies and
        Medical Consequences of Drug Abuse at NIDA                                                                      
“Preclinical studies have shown that AV411 can attenuate the behavioral signs of opioid withdrawal and corresponding glial cell activation without conferring adverse side effects.  My research team and our partners are eager to confirm these findings in humans and help move this potentially important new medicine through clinical development.” (September 2008)
        Sandra D. Comer, Ph.D.
        Associate Professor of Clinical Neurobiology at
        NYSPI and Columbia University

“Development of AV411 for methamphetamine relapse is intriguing and Avigen may be able to obtain Fast-track status and priority review.” (July 2008)
        Cynthia McCormick, M.D.
        McCormick Consulting
        ex-Director of Analgesia and Addiction, CDER                                                                      
“Beyond treating opioid withdrawal symptoms, AV411 may have utility in treating cocaine, methamphetamine and other drug addiction disorders,” “I hope that we can facilitate AV411 development by supporting studies with an expanded focus.  There is truly an unmet medical need for new analgesic approaches with less addiction potential as well as new medications to treat drug addiction disorders.” (February 2009)
        David McCann Ph.D.
        Acting Director of the Division of Pharmacotherapies
        and Medical Consequences of Abuse at the
        National Institute on Drug Abuse (NIDA)

On Avigen’s AV411 (ibudilast) Program

“The ibudilast program is an appealing asset.” (October 2008)  
        Harry Tracy, PhD 
        NeuroInvestment